Nosocomial pneumonia: lessons learned.

Nosocomial pneumonia remains a significant cause of hospital-acquired infection, imposing substantial economic burden on the health care system worldwide. Various preventive strategies have been increasingly used to prevent the development of pneumonia. It is now recognized that patients with health care-associated pneumonia are a heterogeneous population and that not all are at risk for infection with nosocomial pneumonia pathogens, with some being infected with the same organisms as in community-acquired pneumonia. This review discusses the risk factors for nosocomial pneumonia, controversies in its diagnosis, and approaches to the treatment and prevention of nosocomial and health care-associated pneumonia.

[1]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[2]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[3]  M. Niederman,et al.  Respiratory infections and acute lung injury in systemic illness. , 1989, Clinics in chest medicine.

[4]  A. Anzueto,et al.  Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. , 2006, Chest.

[5]  D. Cook,et al.  Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia* , 2008, Critical care medicine.

[6]  Kelly D Peterson,et al.  National Healthcare Safety Network (NHSN) report, data summary for 2009, device-associated module. , 2011, American journal of infection control.

[7]  A. Combes,et al.  Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. , 2005, American journal of respiratory and critical care medicine.

[8]  A. Liapikou,et al.  Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Falagas,et al.  Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis , 2005, Critical care.

[10]  M. Niederman Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. , 2005, Critical care medicine.

[11]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[12]  M. Niederman,et al.  BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia , 2012, Intensive Care Medicine.

[13]  Stijn Vansteelandt,et al.  Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. , 2011, American journal of respiratory and critical care medicine.

[14]  D. Cook,et al.  The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. , 1999, American journal of respiratory and critical care medicine.

[15]  B. Mourvillier,et al.  Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. , 2011, American journal of respiratory and critical care medicine.

[16]  J. Maurer Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care–Associated Pneumonia: A UK Cohort Study , 2012 .

[17]  S. Nseir,et al.  Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients. , 2011, American journal of respiratory and critical care medicine.

[18]  D. Craven,et al.  Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. , 1996, American journal of respiratory and critical care medicine.

[20]  M. Niederman,et al.  De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? , 2011, Clinics in chest medicine.

[21]  R. Platt,et al.  Objective surveillance definitions for ventilator-associated pneumonia* , 2012, Critical care medicine.

[22]  R. Wunderink,et al.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Platt,et al.  Multicenter Evaluation of a Novel Surveillance Paradigm for Complications of Mechanical Ventilation , 2011, PloS one.

[24]  Matthew Bidwell Goetz,et al.  Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. , 2005, Chest.

[25]  M. Klompas,et al.  Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Mathru Continuous Aspiration of Subglottic Secretions in the Prevention of Ventilator-Associated Pneumonia in the Postoperative Period of Major Heart Surgery , 2009 .

[27]  M. Niederman,et al.  Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia , 2009, Current opinion in infectious diseases.

[28]  D. Craven,et al.  Prophylaxis of ventilator-associated pneumonia: changing culture and strategies to trump disease. , 2008, Chest.

[29]  J. Fagon Biological markers and diagnosis of ventilator-associated pneumonia , 2011, Critical care.

[30]  A. Ambergen,et al.  Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. , 1996, American journal of respiratory and critical care medicine.

[31]  M. Niederman The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  B. de Jonghe,et al.  Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. , 2010, American journal of respiratory and critical care medicine.

[33]  Gordon Guyatt,et al.  Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients , 1998, Annals of Internal Medicine.

[34]  F. Saulnier,et al.  First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit* , 2005, Critical care medicine.

[35]  Ronald N. Jones Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  M. Kollef,et al.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Auckenthaler,et al.  Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. , 1991, The American review of respiratory disease.

[38]  D. Mozingo A randomized trial of diagnostic techniques for ventilator-associated pneumonia. , 2006, The New England journal of medicine.

[39]  R. Cantor,et al.  Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. , 2001, American journal of respiratory and critical care medicine.

[40]  J. Barker A Randomized Trial of Diagnostic Techniques for Ventilator-Associated Pneumonia , 2008 .

[41]  Kara E. Flavin,et al.  Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. , 2003, Chest.

[42]  T. Welte,et al.  Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study , 2011, Thorax.

[43]  M. Kollef,et al.  Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  A. Combes,et al.  Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  T. Walsh,et al.  Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle* , 2011, Critical care medicine.

[46]  Richard Platt,et al.  Rapid and reproducible surveillance for ventilator-associated pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  R. Grossman,et al.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[48]  J. Ramirez,et al.  Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. , 2011, The Lancet. Infectious diseases.

[49]  F. Jacobs Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. , 2011, Critical care medicine.

[50]  A. Bianco,et al.  Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied antimicrobial or antiseptic agents: a meta-analysis of randomized controlled trials in intensive care units , 2011, Critical care.

[51]  L. Tsu,et al.  Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia , 2010, Infection.

[52]  W. Cui,et al.  Effect of Procalcitonin-Guided Treatment in Patients with Infections: a Systematic Review and Meta-Analysis , 2009, Infection.

[53]  Y. Chuang,et al.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.

[54]  A. Marra,et al.  A program for sustained improvement in preventing ventilator associated pneumonia in an intensive care setting , 2012, BMC Infectious Diseases.

[55]  J. Rello,et al.  New issues and controversies in the prevention of ventilator-associated pneumonia. , 2010, American journal of respiratory and critical care medicine.

[56]  Roger Resar,et al.  Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. , 2005, Joint Commission journal on quality and patient safety.

[57]  M. Niederman The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. , 2006, Seminars in Respiratory and Critical Care Medicine.

[58]  Q. Lu,et al.  Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.

[59]  D. Craven,et al.  Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. , 2009, Chest.

[60]  D. Baram,et al.  Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit* , 2008, Critical care medicine.

[61]  Sanjay Saint,et al.  Clinical and economic consequences of ventilator-associated pneumonia: A systematic review , 2005, Critical care medicine.

[62]  M. Niederman Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[64]  L. Mandell,et al.  Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement , 1996 .

[65]  J. Chastre,et al.  Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. , 1989, The American review of respiratory disease.

[66]  D. Cook,et al.  Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. , 2008, Journal of critical care.

[67]  A. Shorr,et al.  Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  M. Klompas Is a ventilator-associated pneumonia rate of zero really possible? , 2012, Current opinion in infectious diseases.

[69]  D. Nicolau,et al.  Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. , 2010, Journal of critical care.

[70]  D. Paterson,et al.  What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. , 2012, International journal of antimicrobial agents.

[71]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[72]  S. Corrao,et al.  Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study , 2012, Internal and Emergency Medicine.

[73]  J. Bartlett,et al.  Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia , 2004 .

[74]  M. Niederman,et al.  Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* , 2003, Critical care medicine.

[75]  M. Kollef,et al.  Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. , 2009, Chest.

[76]  A. Vuagnat,et al.  Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. , 1998, American journal of respiratory and critical care medicine.

[77]  J. Pépin,et al.  Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.

[78]  R. Favory,et al.  Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study , 2008, Critical care.

[79]  A. Anzueto,et al.  Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. , 2008, JAMA.

[80]  D. Dreyfuss,et al.  Prospective study of nosocomial pneumonia and of patient and circuit colonization during mechanical ventilation with circuit changes every 48 hours versus no change. , 1991, The American review of respiratory disease.

[81]  Jordi Rello,et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.

[82]  T. Karchmer,et al.  Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. , 2006, Chest.

[83]  F. Saulnier,et al.  Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome , 2002, European Respiratory Journal.

[84]  A. Anzueto,et al.  Guideline-concordant therapy and outcomes in healthcare-associated pneumonia , 2011, European Respiratory Journal.

[85]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[86]  A. Anzueto,et al.  Incidence, risk factors, and outcome of ventilator-associated pneumonia. , 2006, Journal of critical care.

[87]  A J DeRiso,et al.  Chlorhexidine Gluconate 0.12% Oral Rinse Reduces the Incidence of Total Nosocomial Respiratory Infection and Nonprophylactic Systemic Antibiotic Use in Patients Undergoing Heart Surgery , 1996, Chest.

[88]  A. E. El Solh,et al.  Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.